Literature DB >> 2453974

Inactivation and partition of human immunodeficiency virus during Kistler and Nitschmann fractionation of human blood plasma.

Y Hénin1, V Maréchal, F Barré-Sinoussi, J C Chermann, J J Morgenthaler.   

Abstract

We studied the inactivation of the etiologic agent of the acquired immunodeficiency syndrome, human immunodeficiency virus, in the course of the Kistler and Nitschmann cold ethanol fractionation of human blood plasma. By measuring reverse transcriptase activity and viral infectivity, we have shown that the virus load is reduced by a factor of 10(4) during the initial and at least a factor of 10(6) during the subsequent steps of the fractionation procedure. This loss of virus may be observed in the absence or in the presence of antibodies against human immunodeficiency virus and is due to a combination of chemical inactivation, physical partition, and injury caused by repeated freezing and thawing. The laboratory data therefore further confirm epidemiological studies which indicate that immunoglobulin preparations obtained by ethanol fractionation do not transmit human immunodeficiency virus.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2453974     DOI: 10.1111/j.1423-0410.1988.tb01621.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  4 in total

1.  Intravenous immunoglobulin in the treatment of paediatric cerebral malaria.

Authors:  T E Taylor; M E Molyneux; J J Wirima; A Borgstein; J D Goldring; M Hommel
Journal:  Clin Exp Immunol       Date:  1992-12       Impact factor: 4.330

Review 2.  Virus safety of intravenous immunoglobulin: future challenges.

Authors:  Nicola Boschetti; Martin Stucki; Peter J Späth; Christoph Kempf
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

3.  Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins.

Authors:  Christoph Kempf; Martin Stucki; Nicola Boschetti
Journal:  Biologicals       Date:  2006-04-03       Impact factor: 1.856

Review 4.  Intravenous immunoglobulins: evolution of commercial IVIG preparations.

Authors:  John A Hooper
Journal:  Immunol Allergy Clin North Am       Date:  2008-11       Impact factor: 3.479

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.